MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MYC paralogs are frequently activated in small cell lung cancer (SCLC).
• MYC paralogs are challenging drug targets in SCLC.
• Understanding MYC-paralog-specific vulnerabilities is crucial for SCLC therapy development.

Purpose of the Study:

• To map MYC-paralog-specific vulnerabilities in SCLC.
• To investigate the role of MYC in regulating BCL2 transcription.
• To identify novel therapeutic strategies for MYC-driven SCLC.

Main Methods:

• Utilized a CRISPR activation model for MYC paralog studies.
• Analyzed MYC's interaction with MIZ1 and DNMT3a in BCL2 regulation.
• Assessed sensitivity to cell cycle and DNA damage checkpoint inhibitors.
• Evaluated combined AURK and CHK1 inhibition in a mouse SCLC model.

Main Results:

• MYC, unlike MYCN and MYCL, represses BCL2 transcription via MIZ1 and DNMT3a.
• MYC activation leads to BCL2 downregulation, increasing sensitivity to cell cycle inhibition and MCL1 dependency.
• MYC activation results in heightened apoptotic priming, genotoxic stress, and susceptibility to DNA damage checkpoint inhibitors.
• Combined AURK and CHK1 inhibition significantly improved survival in MYC-driven SCLC mouse models compared to chemotherapy.

Conclusions:

• MYC-paralog-specific regulation of the apoptotic machinery in SCLC identified.
• MYC-driven SCLC exhibits unique vulnerabilities exploitable by targeted therapies.
• Combined AURK and CHK1 inhibition presents a promising therapeutic strategy for SCLC patients with MYC activation.